SciELO - Scientific Electronic Library Online

 
vol.32 issue3Polypharmacy in HIV patient older than 50 yearsImplementation of Comprehensive Medication Management in Costa Rican patients with chronic kidney disease author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista de la OFIL

On-line version ISSN 1699-714XPrint version ISSN 1131-9429

Abstract

CANTARELLI, L; GUTIERREZ, NF; NAZCO-CASARIEGO, GJ  and  GONZALEZ-GARCIA, J. Incidence of hypokalemia in patients with febrile neutropenia receiving treatment with liposomal amphotericin B. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.3, pp.263-266.  Epub Sep 25, 2023. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2022000300009.

Objectives:

To describe the incidence, severity and factors associated with the appearance of hypokalemia in patients with febrile neutropenia in treatment with liposomal amphotericin B.

Methods:

Retrospective unicenter study (January 2010-May 2020), which included those hematological patients with febrile neutropenia who were treated with liposomal amphotericin B for at least 72 h. The incidence of hypokalemia associated with the use of the drug, itsseverity, and the influence of potassiumsupplementation on the occurrence ofhypokalemia in this group of patientswere evaluated.

Results:

89 patients were included (50.6% women [n=45]; mean age 63.5 years [20-90]). 59.6% (n=53) of patients developed hypokalemia during treatment with liposomal amphotericin B: mild (52.8%, n=28), moderate (35.8%, n=19) and severe (11.3%, n=6). The use of early-onset potassium-based supplementation decreased the rate of occurrence of hypokalemia in these patients (p=0.001). The period between drug initiation and potassium intake was lower in patients who did not develop hypokalemia (p<0.001). Likewise, this group of patients benefited from longer periods of supplementation (p=0.002) and antifungal therapy (p=0.039).

Conclusions:

Hypokalemia is a very frequent adverse effect in patients with febrile neutropenia who are treated with liposomal amphotericin B. It is necessary to establish protocols for potassium supplementation to reduce the risk of this adverse reaction.

Keywords : Hypokalemia; febrile neutropenia; liposomal amphotericin B; antifungal agents; adverse effects.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )